BiotechTube

Placebo + 0.5 mg epinephrine + 1 mg epinephrine

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urticaria Chronic

Conditions

Urticaria Chronic

Trial Timeline

Jul 9, 2025 → Jun 1, 2026

NCT ID
NCT06927999

About Placebo + 0.5 mg epinephrine + 1 mg epinephrine

Placebo + 0.5 mg epinephrine + 1 mg epinephrine is a phase 2 stage product being developed by ARS Pharmaceuticals for Urticaria Chronic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06927999. Target conditions include Urticaria Chronic.

What happened to similar drugs?

8 of 20 similar drugs in Urticaria Chronic were approved

Approved (8) Terminated (3) Active (10)
✅OMALIZUMABNovartisApproved
✅Levocetirizine + Levocetirizine plus HydroxyzineUCBApproved
✅Levocetirizine + DesloratadineUCBApproved
✅desloratadine + placebo + cetirizineOrganonApproved
✅Desloratadine + Cetirizine + placeboOrganonApproved
✅5-mg Desloratadine + 10-mg Desloratadine + 20-mg DesloratadineOrganonApproved
✅desloratadine + desloratadineOrganonApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06927999Phase 2Recruiting

Competing Products

20 competing products in Urticaria Chronic

See all competitors
ProductCompanyStageHype Score
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
CT-P39 + EU-approved XolairCelltrionPhase 3
40
OmalizumabCelltrionPre-clinical
33
LY3454738 + PlaceboEli LillyPhase 2
27
AZD1981 + PlaceboAstraZenecaPhase 2
35
Benralizumab + Placebo and BenralizumabAstraZenecaPhase 2
27
LOU064NovartisPhase 3
40
Ligelizumab + OmalizumabNovartisPhase 3
40
Ligelizumab + PlaceboNovartisPhase 1
21
OmalizumabNovartisPhase 2
35
canakinumabNovartisPhase 2
35
LOU064NovartisPhase 2
35
Omalizumab (Xolair) + PlaceboNovartisPhase 2/3
38
LOU064 Arm 1 + LOU064 Arm 2 + LOU064 Arm 3 + LOU064 Arm 4 + LOU064 Arm 5 + LOU064 Arm 6 + Placebo armNovartisPhase 2
35
LOU064 (blinded) + placeboNovartisPhase 3
47
Remibrutinib + Remibrutinib matching placebo + Dupilumab + Placebo solution for injectionNovartisPhase 3
47